The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma
Author: admin
The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma
Saad Usmani, MD Levine Cancer Institute Charlotte, NC discusses the Dana Farber IFM 2009 Phase III Study of the Intergroupe Francophone Du Myelome from ASH 2015
Brian T. Hill , MD, PhD Assistant Professor, Medicine, Case Western Reserve University School of Medicine (Cleveland Clinic) discusses how BCR Signaling Inhibitors Extremely Active and Generally Well Tolerated from ASH 2015
Brian T. Hill , MD, PhD Assistant Professor, Medicine, Case Western Reserve University School of Medicine (Cleveland Clinic) discusses the Practice Changing Drugs for CLL from ASH 2015
Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses the fact that Precision Medicine Coming to Bone Marrow Transplant
Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses Pre Transplant Depression Linked to Lower Overall Survival in Post Transplant Patients
Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses a Phase 3 Randomized Trial Support High Intensity Conditioning with Myeloablative Regimens in AML
Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how Ixazomib Has Not Shown The Cardiotoxicity of Injectable Proteasome Inhibitors
Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic talks about how Elotuzumab Shows Benefits When Treated Early in Multiple Myeloma
Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how Daratumumab will Play Increasingly Important Role in Treating Multiple Myeloma According to ASH 2015 Data
Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic talks about new ASH 2015 Data That Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab
Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the importance of the RESONATE-2 Trial Results Most Likely To Move Ibrutinib to Frontline in 2016
Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses Precautions and Suggestions Regarding Management of Adverse Events of BCR Signaling Inhibitors
Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses MD Andersons Real World Experience With BCR signaling Inhibitors in CLL
Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the nd to Chemotherapy in CLL Most Likely as Targeted and Immunotherapy Move to Frontline
Chemotherapy-induced nausea and vomiting (CINV) remains a concern for many cancer patients. At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Cheryl Vidall, Head of Nursing and Governance at Alcura UK Limited, Alton, UK, discusses current approaches for optimising the management of CINV. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ruth Hammond, Vascular Access and IV Nurse Practitioner, and Clinical Practice Educator at The Royal Marsden NHS Foundation Trust, London, UK, discusses the initial findings of an audit of the experiences of wearing medical alert bands in patients with suspected neutropenic sepsis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Henry, President Elect of the UKONS, and Teaching Fellow at the School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK, explains the purpose of the UKONS, which includes promoting high standards in the nursing management and care of individuals affected by cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of the United Kingdom Oncology Nursing Society (UKONS), which is run by cancer nurses for cancer nurses, and the UKONS Annual Conference 2015. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care, Cardiff, Wales, discusses the impact of the Tenovus Cancer Care Sing with Us choirs, which are open to anyone affected by cancer, on those that participate. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, explains the potential benefits of lifestyle choices, including interventions on diet and physical activity, for cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, reviews the scientific and societal challenges of drug development for the treatment of patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Ibrutinib or Idelalisib Selecting Appropriate Therapy for Relapsed CLL
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Entospletinib Why Its Different Than Fostamatinib
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology talks about how CLL has been Transformed in Last 5 Years and that the Hope is to Leave Chemotherapy Behind
Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses ASH 2015 highlights as Bcl-2, BTK, and PI3 Inhibitors
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about how Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some Toxicity
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses Ibrutinib or Idelalisib Preferred in Relapsed Patients Over Chemotherapy for CLL.
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses Chlorambucil v. Ibrutinib Shows Ibrutinib Powerful in Older Patients with CLL from ASH 2015
Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about the Adverse Events with Idelalisib + Rituximab May Be Autoimmune Related from ASH 2015
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses Imetelstat Pilot Study Data Released for MPN Patients
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PRM-151 Phase III Study Results in Myelofibrosis
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PERSIST-1 Phase III Study Results of Pacritinib from ASH 2015
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how the COMFORT II Study Shows Ruxolitinib as a Very Durable Treatment for MPN from ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Real World Experience with Approved BCR Signaling Inhibitors at ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses R-CHOP With or Without Bortezomib Results at ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses the New CAR T-Cell Studies Launching Now from ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Natural Therapeutic Partners for BCR Signaling Inhibitors at ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Ibrutinib in Mantle Cell Lymphoma report from ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Atrial Fibrillation in Patients with CLL report from ASH 2015
Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses ABT-199 Data Released at ASH 2015
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Real World Experience with Ibrutinib and Idelalisib from ASH 2015
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Novel Nucleoside Analog Ribose Sugar in AML at ASH 2015
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Map Kinase Pathway P-38 in CLL
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Choosing a BCR Signaling Inhibitor in CLL from ASH 2015
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about ASH 2015 Highlights for Myeloma Treatments
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses the latest Advances In B-Cell Lymphoma From ASH 2015
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Second Generation B2K Inhibitors Look Promising ACP-196 & BGB-3111 at ASH 2015